Achieve Life Sciences, Inc. Net Fee Amt
Achieve Life Sciences, Inc. (ACHV) had Net Fee Amt of $69.07 thousand as of 2026-05-12, per its S-3 filed 2026-05-12.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-12
- 2026-05-12: Net Fee Amt $69.07K.
- 2026-04-16: Net Fee Amt $7.75K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-12 | $69.07K S-3 · filed 2026-05-12 |
| 2026-04-16 | $7.75K S-8 · filed 2026-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |